ImmunogenX Invited to Present at the Medical Device & Investor Forum

The company presents its business plan at this select showcase

ImmunogenX, a biopharmaceutical company focused on the diagnosis and treatment of celiac disease, announced that it was a select invited presenter at the Medical Device & Investor Forum (MDIF) held in Irvine, CA on October 27-28, 2016. MDIF is the largest life science conference in Southern California focused on high growth and innovation technology investment. OCTANe, the organizer of the event, is dedicated to developing and advancing the technology business base in Southern California. MDIF provided the opportunity for ImmunogenX to present its business plan in the presence of leading venture capital firms as well as senior executives in the industry.

Jack Syage, CEO of ImmunogenX remarked, “MDIF is one of the leading forums in California dedicated to bridging promising technology companies with sources to grow through investments and strategic partnerships. We were ecstatic to be one of the very few companies selected to present at this prestigious gathering.”

Bill Carpou, President and CEO of OCTANe commented, “ImmunogenX was chosen from a very competitive pool of outstanding companies in the health care and medical technology field. They impressed the panel with their mature technology, management team, business acumen, and investor opportunity. It is also worth noting that ImmunogenX won the fast pitch competition in a preconference event. We look forward to continuing our assistance to ImmunogenX on their road to success.”

About ImmunogenX

ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company recently acquired Latiglutenase (ALV003) for celiac disease therapy, which is currently in Phase 2 clinical trials. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye and has developed the first multiplexed analytical method to detect and quantify trace levels of gluten and other allergens in food and consumer products.

www.immunogenx.com

For further information please contact

Matthew Dickason, COO
949 679-0900
mdickason@immunogenx.com